US5716949A - Heterocyclic compounds - Google Patents
Heterocyclic compounds Download PDFInfo
- Publication number
- US5716949A US5716949A US08/625,562 US62556296A US5716949A US 5716949 A US5716949 A US 5716949A US 62556296 A US62556296 A US 62556296A US 5716949 A US5716949 A US 5716949A
- Authority
- US
- United States
- Prior art keywords
- subject
- compound
- alkoxy
- pharmaceutical composition
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
- the invention also relates to the use of the present compounds for the treatment of insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) or aging, the present compounds knowing to interfere with neuropeptide containing C-fibers and hence inhibit the secretion and circulation of insulin antagonizing peptides like CGRP or amylin.
- NIDDM non-insulin-dependent diabetes mellitus
- the nervous system exerts a profound effect on the inflammatory response.
- Antidromic stimulation of sensory nerves results in localized vasodilation and increased vascular permeability (Janecso et al. Br. J. Pharmacol. 1967, 31, 138-151) and a similar response is observed following injection of peptides known to be present in sensory nerves. From this and other data it is postulated that peptides released from sensory nerve endings mediate many inflammatory responses in tissues like skin, joint, urinary tract, eye, meninges, gastro-intestinal and respiratory tracts.
- inhibition of sensory nerve peptide release and/or activity may be useful in treatment of, for example arthritis, dermatitis, rhinitis, asthma, cystitis, gingivitis, thrombophlelitis, glaucoma, gastro-intestinal diseases or migraine.
- CGRP may play a physiological role in skeletal muscle glucose metabolism by directing the phosphorylated glucose away from glycogen storage and into the glycolytic and oxidative pathways (Rossetti et al. Am. J. Physiol. 264, E1-E10, 1993).
- This peptide may represent an important physiological modulator of intracellular glucose trafficking in physiological conditions, such as exercise, and may also contribute to the decreased insulin action and skeletal muscle glycogen synthase in pathophysiological conditions like NIDDM or aging-associated obesity (Melnyk et al. Obesity Res. 3, 337-344, 1995) where circulating plasma levels of CGRP are markedly increased.
- inhibition of release and/or activity of the neuropeptide CGRP may be useful in the treatment of insulin resistance related to type 2 diabetes or aging.
- N-substituted azacyclic carboxylic acids are claimed as GABA uptake inhibitors.
- the present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof of formula I ##STR1## wherein R 1 and R 2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, C 1-6 -alkyl or C 1-6 -alkoxy; and
- Y is >N--CH 2 --, >CH--CH 2 -- or >C ⁇ CH-- wherein only the underscored atom participates in the ring system;
- X is ortho phenylene, --CH 2 --(C ⁇ O)--, --(C ⁇ O)--CH 2 --, --CH 2 --S--, --S--CH 2 --, --CH 2 --N(R 8 )--, --N(R 8 )--CH 2 , --N(CH 3 )--SO 2 --, --SO 2 --N(CH 3 )--, --CH(R 7 )--CH 2 -- or --CH 2 --CH(R 7 )--- wherein R 8 is hydrogen or C 1-6 -alkyl and R 7 is C 1-6 -alkyl or phenyl; and
- r is 1, 2 or 3;
- n 1 or 2;
- n 1 when m is 1 and n is 0 when m is 2;
- R 3 and R 4 each represents hydrogen or may--when m is 2--together represent a bond
- R 5 is --OH or C 1-6 -alkoxy
- the compounds of formula I may exist as geometric and optical isomers and all isomers and mixtures thereof are included herein. Isomers may be separated by means of standard methods such as chromatographic techniques or fractional crystallization of suitable salts.
- the compounds of formula I exist as the individual geometric or optical isomers.
- the compounds according to the invention may optionally exist as pharmaceutically acceptable acid addition salts or--when the carboxylic acid group is not esterified--as pharmaceutically acceptable metal salts or--optionally alkylated--ammonium salts.
- salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate or similar pharmaceutically acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in journal of Pharmaceutical Science, 66, 2 (1977) which are hereby incorporated by reference.
- C 1-6 -alkyl refers to a straight or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms such as e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, n-hexyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl and 1,2,2-trimethylpropyl.
- C 1-6 -alkoxy refers to a straight or branched monovalent substituent comprising a C 1-6 -alkyl group linked through an ether oxygen having its free valence bond from the ether oxygen and having 1 to 6 carbon atoms e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy.
- halogen means fluorine, chlorine, bromine or iodine.
- the term "patient” includes any mammal which could benefit from treatment of neurogenic pain or inflammation or insulin resistance in NIDDM.
- the term particularly refers to a human patient, but is not intended to be so limited.
- novel compounds of formula I inhibit neurogenic inflammation which involves the release of neuropeptides from peripheral and central endings of sensory C-fibers. Experimentally this can be demonstrated in animal models of formalin induced pain or paw oedema (Wheeler and Cowan, Agents Actions 1991, 34, 264-269) in which the novel compounds of formula I exhibit a potent inhibitory effect.
- Compounds of formula I may be used to treat all painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation, i.e.:
- Acutely painful conditions exemplified by migraine, postoperative pain, burns, bruises, post-herpetic pain (Zoster) and pain as it is generally associated with acute inflammation; chronic, painful and/or inflammatory conditions exemplified by various types of neuropathy (diabetic, post-traumatic, toxic), neuralgia, rheumatoid arthritis, spondylitis, gout, inflammatory bowel disease, prostatitis, cancer pain, chronic headache, coughing, asthma, chronic pancreatitis, inflammatory skin disease including psoriasis and autoimmune dermatoses, osteoporotic pain.
- neuropathy diabetic, post-traumatic, toxic
- neuralgia rheumatoid arthritis
- spondylitis gout
- inflammatory bowel disease exemplified by various types of neuropathy (diabetic, post-traumatic, toxic), neuralgia, rheumatoid arthritis, spondylitis, gout,
- the compounds of general formula I improves the glucose tolerance in diabetic oblob mice and that this may result from the reduced release of CGRP from peripheral nervous endings.
- the compounds of general formula I may be used in the treatment of NIDDM as well as aging-associated obesity. Experimentally this has been demonstrated by the subcutaneous administration of glucose into ob/ob mice with or without previous oral treatment with a compound of general formula I.
- the compounds of formula I may be prepared by the following method: ##STR2##
- a compound of formula II wherein R 1 , R 2 , X, Y and r are as defined above and W is a suitable leaving group such as halogen, p-toluene sulphonate or mesylate may be reacted with an azaheterocyclic compound of formula III wherein R 3 , R 4 , R 5 , m and n are as defined above.
- This alkylation reaction may be carried out in a solvent such as acetone, dibutylether, 2-butanone, methyl ethyl ketone, ethyl acetate, tetrahydrofuran (THF) or toluene in the presence of a base e.g.
- esters have been prepared in which R 5 is alkoxy
- compounds of formula I wherein R 5 is OH may be prepared by hydrolysis of the ester group, preferably at room temperature in a mixture of an aqueous alkali metal hydroxide solution and an alcohol such as methanol or ethanol, for example, for about 0.5 to 6 h.
- the carboxylic acid group can, for example, be esterified. Introduction and removal of such groups is described in "Protective Groups in Organic Chemistry” J. F. W. McOrnie ed. (New York, 1973).
- mice About 20 g NMRI female mice were injected 20 ml 1% formalin into the left hind paw. The animals were then placed on a heated (31° C.) table, and the pain response was scored. After 1 h they were killed and bled. Left and right hind paws were removed and the weight difference between the paws was used as indication of the oedema response of the formalin injected paw.
- mice 16 weeks of age, where injected glucose (2 g/kg) subcutaneously.
- blood glucose was determined in tail venous blood by the glucose oxidase method.
- glucose oxidase method was determined in tail venous blood by the glucose oxidase method.
- Immunoreactive CGRP was determined in plasma by radio-immuno-assay. Two groups of animals were used. The one group was vehicle treated, whereas the other group received a compound of formula I via drinking water (100 mg/l) for five days before the test.
- dosages suitable for oral administration comprise from about 0.5 mg to about 1000 mg, preferably from about 1 mg to about 500 mg of the compounds of formula I admixed with a pharmaceutical carrier or diluent.
- the compounds of formula I may be administered in a pharmaceutically acceptable acid addition salt form or where possible as a metal or a lower alkylammonium salt. Such salt forms exhibit approximately the same order of activity as the free base forms.
- compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof and, usually, such compositions also contain a pharmaceutical carrier or diluent.
- compositions containing the compounds of this invention may be prepared by conventional techniques and appear in conventional forms, for example capsules, tablets, solutions or suspensions.
- the pharmaceutical carrier employed may be a conventional solid or liquid carrier.
- solid carriers are lactose, terra alba, sucrose, talc, gelatine, agar, pectin, acacia, magnesium stearate and stearic acid.
- liquid carriers are syrup, peanut oil, olive oil and water.
- the carrier or diluent may include any time delay material known to the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- the preparation can be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge.
- the amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
- the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or nonaqueous liquid suspension or solution.
- the compounds of this invention are dispensed in unit dosage form comprising 50-200 mg of active ingredient in or together with a pharmaceutically acceptable carrier per unit dosage.
- the dosage of the compounds according to this invention is 1-500 mg/day, e.g. about 100 mg per dose, when administered to patients, e.g. humans, as a drug.
- a typical tablet which may be prepared by conventional tabletting techniques contains
- the route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, subcutaneous, intranasal, intramuscular, topical, intravenous, intraurethral, ophthalmic solution or an ointment, the oral route being preferred.
- oral or parenteral e.g. rectal, transdermal, subcutaneous, intranasal, intramuscular, topical, intravenous, intraurethral, ophthalmic solution or an ointment, the oral route being preferred.
- n-Butyl lithium (1.0 ml, 2.7 mmol, 2.7M in n-hexane) was added dropwise at 0° C. and the reaction mixture was stirred at 0° C. for 0.5 hour.
- 1-Bromo-3-chloropropane (0.5 g, 3.1 mmol) dissolved in dry tetrahydrofuran (1 ml) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 2 hours.
- n-Butyl lithium (2.5 ml, 5.4 mmol, 2.7M in n-hexane) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 18 hours.
- the combined organic extracts were washed with brine (80 ml), dried (MgSO 4 ), filtered and the solvent was evaporated in vacuo.
- the crude product (2.0 g) was purified by column chromatography on silica gel (600 ml) using a mixture of ethyl acetate, heptane and triethyiamine (10:20:0.01) as eluent.
- reaction mixture was quenched with saturated ammonium chloride (50 ml) and extracted with ethyl acetate (2 ⁇ 200 ml).
- the combined organic extracts were washed with water (2 ⁇ 100 ml) and dried (Na 2 SO 4 ), filtered and the solvent was evaporated in vacuo.
- the residue was dissolved in dichloromethane (20 ml) and filtered.
- the filtrated was evaporated in vacuo and the residue crude product was purified by column chromatography on silica gel (800 ml) using dichloromethane as eluent and later on ethyl acetate as eluent.
- the precipitate was separated and dissolved in water (50 ml). The resulting mixture was washed with dichloromethane (2 ⁇ 50 ml) and diethyl ether (2 ⁇ 50 ml). The aqueous phase was evaporated in vacuo and the residue was suspended in 2-propanol (100 ml), stirred 0.5 hour at room temperature and filtered. The filtrate was evaporated in vacuo and triturated with diethyl ether (50 ml), filtered off, and washed with diethyl ether. The filtercake (0.93 g) was stirred with 2-propanol (15 ml) for 2 hours, the precipitate filtered off and washed with 2-propanol.
- lithium aluminumhydride (4.2 g, 0.112 mol) was suspended in dry diethyl ether (200 ml) under a nitrogen atmosphere.
- a solution of 5-methyl-5H-dibenz b,e!azepin-6,11-dione-11-ethylene ketal (30.0 g, 0.11 mol) in dry tetrahydrofuran (250 ml) was added dropwise.
- the mixture was heated at reflux temperature for 1.5 hour, cooled to room temperature and quenched by cautious addition of water (4 ml) and 25% sodium hydroxide (4 ml), MgSO 4 and filtered.
- HPLC retention time 18.03 minutes (5mm C18 4 ⁇ 250 mm column, eluting with a 20-80% gradient of 0.1% trifluoroacetic acid/acetonitrile and 0.1% trifluoroacetic acid/water over 25 minutes at 35° C.).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/862,169 US5753643A (en) | 1995-04-07 | 1997-05-22 | Heterocyclic compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK40695 | 1995-04-07 | ||
DK0406/95 | 1995-04-07 | ||
DK1003/95 | 1995-09-11 | ||
DK100395 | 1995-09-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/862,169 Division US5753643A (en) | 1995-04-07 | 1997-05-22 | Heterocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US5716949A true US5716949A (en) | 1998-02-10 |
Family
ID=26063930
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/625,562 Expired - Fee Related US5716949A (en) | 1995-04-07 | 1996-03-28 | Heterocyclic compounds |
US08/862,169 Expired - Fee Related US5753643A (en) | 1995-04-07 | 1997-05-22 | Heterocyclic compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/862,169 Expired - Fee Related US5753643A (en) | 1995-04-07 | 1997-05-22 | Heterocyclic compounds |
Country Status (9)
Country | Link |
---|---|
US (2) | US5716949A (xx) |
EP (1) | EP0869954B1 (xx) |
JP (1) | JPH11503128A (xx) |
AT (1) | ATE205843T1 (xx) |
AU (1) | AU5100496A (xx) |
CA (1) | CA2217130A1 (xx) |
DE (1) | DE69615397D1 (xx) |
IL (1) | IL117811A0 (xx) |
WO (1) | WO1996031499A1 (xx) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004983A (en) * | 1996-10-04 | 1999-12-21 | Novo Nordisk A/S | N-substituted azaheterocyclic compounds |
US6569849B1 (en) * | 1996-10-04 | 2003-05-27 | Novo Nordisk A/S | N-Substituted azaheterocyclic compounds |
US20050216674A1 (en) * | 2001-10-22 | 2005-09-29 | Apple Computer, Inc. | Media player with instant play capability |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3968217A (en) * | 1974-04-22 | 1976-07-06 | A. H. Robins Company, Incorporated | 5-(3-)SUBSTITUTED-10,11-DIHYDRO-5H-dibenz[b,f]azepines |
US3993757A (en) * | 1975-06-06 | 1976-11-23 | Richardson-Merrell Inc. | Method of treating inflammation with morphanthridines |
US4181655A (en) * | 1973-08-24 | 1980-01-01 | Research Institute For Medicine And Chemistry Inc. | 5(3-Substituted aminopropyl)-10-trifluoromethoxy-5H-dibenz[b,f]azepines |
US5595989A (en) * | 1994-01-04 | 1997-01-21 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL256053A (xx) * | 1959-09-22 | |||
US3391136A (en) * | 1963-09-13 | 1968-07-02 | Boehringer Sohn Ingelheim | 3-chloro-11-(upsilan-dimethylaminopropylidene)-5, 6-dihydromorphanthridine and derivatives |
US3381000A (en) * | 1963-10-16 | 1968-04-30 | Colgate Palmolive Co | Certain 11-basic substituted-5, 6-dihydromorphanthridine compounds |
US3542790A (en) * | 1966-12-07 | 1970-11-24 | Mead Johnson & Co | Substituted 5,11-dihydro-10,10-dioxodibenzo(c,f)(1,2)thiazepines |
FR2594827B1 (fr) * | 1986-02-21 | 1988-05-20 | Adir | Nouveau derive tricyclique denomme acide ((chloro-3 methyl-6 dioxo-5,5 dihydro-6, 11 dibenzo (c,f) thiazepine (1,2) yl-11 amino)-5 pentazoique, son procede de preparation et les compositions pharmaceutiques qui le contiennent |
IT1225729B (it) * | 1988-08-12 | 1990-11-26 | Menarini S A S Firenze A | Derivati della 5,5-diossido-6,11-diidrodibenzo (c,f)(1,2,5) tiadiazepina, loro sali e relativi procedimenti di fabbricazione |
-
1996
- 1996-03-28 US US08/625,562 patent/US5716949A/en not_active Expired - Fee Related
- 1996-04-01 AT AT96907328T patent/ATE205843T1/de not_active IP Right Cessation
- 1996-04-01 WO PCT/DK1996/000140 patent/WO1996031499A1/en active IP Right Grant
- 1996-04-01 CA CA002217130A patent/CA2217130A1/en not_active Abandoned
- 1996-04-01 DE DE69615397T patent/DE69615397D1/de not_active Expired - Lifetime
- 1996-04-01 JP JP8529869A patent/JPH11503128A/ja active Pending
- 1996-04-01 AU AU51004/96A patent/AU5100496A/en not_active Abandoned
- 1996-04-01 EP EP96907328A patent/EP0869954B1/en not_active Expired - Lifetime
- 1996-04-03 IL IL11781196A patent/IL117811A0/xx unknown
-
1997
- 1997-05-22 US US08/862,169 patent/US5753643A/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4181655A (en) * | 1973-08-24 | 1980-01-01 | Research Institute For Medicine And Chemistry Inc. | 5(3-Substituted aminopropyl)-10-trifluoromethoxy-5H-dibenz[b,f]azepines |
US3968217A (en) * | 1974-04-22 | 1976-07-06 | A. H. Robins Company, Incorporated | 5-(3-)SUBSTITUTED-10,11-DIHYDRO-5H-dibenz[b,f]azepines |
US3993757A (en) * | 1975-06-06 | 1976-11-23 | Richardson-Merrell Inc. | Method of treating inflammation with morphanthridines |
US5595989A (en) * | 1994-01-04 | 1997-01-21 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters thereof |
Non-Patent Citations (6)
Title |
---|
Nakanishi, et al., Journal of Medicinal Chemistry, vol. 13, No. 4, pp. 664 648 (1970). * |
Nakanishi, et al., Journal of Medicinal Chemistry, vol. 13, No. 4, pp. 664-648 (1970). |
Sindelar et al., Antihistamine Substances. Tricyclic Analogues of N (4,4 Diphenyl 3 butene 1 yl)Nipecotic Acid and some related compounds, Collect. Czech. Chem. Commun., vol. 59, pp. 667 674, 1994. * |
Sindelar et al., Antihistamine Substances. Tricyclic Analogues of N-(4,4-Diphenyl-3-butene-1-yl)Nipecotic Acid and some related compounds, Collect. Czech. Chem. Commun., vol. 59, pp. 667-674, 1994. |
Sindelar, et al., Collect. Czech. Chem. Commun., vol. 59, pp. 667 675, (1994). * |
Sindelar, et al., Collect. Czech. Chem. Commun., vol. 59, pp. 667-675, (1994). |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004983A (en) * | 1996-10-04 | 1999-12-21 | Novo Nordisk A/S | N-substituted azaheterocyclic compounds |
US6569849B1 (en) * | 1996-10-04 | 2003-05-27 | Novo Nordisk A/S | N-Substituted azaheterocyclic compounds |
US20050216674A1 (en) * | 2001-10-22 | 2005-09-29 | Apple Computer, Inc. | Media player with instant play capability |
Also Published As
Publication number | Publication date |
---|---|
US5753643A (en) | 1998-05-19 |
EP0869954B1 (en) | 2001-09-19 |
DE69615397D1 (de) | 2001-10-25 |
EP0869954A1 (en) | 1998-10-14 |
WO1996031499A1 (en) | 1996-10-10 |
JPH11503128A (ja) | 1999-03-23 |
IL117811A0 (en) | 1996-08-04 |
CA2217130A1 (en) | 1996-10-10 |
ATE205843T1 (de) | 2001-10-15 |
AU5100496A (en) | 1996-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0738262B1 (en) | Novel heterocyclic compounds | |
EP0820451B1 (en) | Novel heterocyclic compounds | |
US5750518A (en) | Heterocyclic compounds | |
WO1996031469A1 (en) | N-substituted azaheterocyclic carboxylic acids and esters thereof | |
US6004983A (en) | N-substituted azaheterocyclic compounds | |
US6166009A (en) | N-substituted azaheterocyclic carboxylic acids and esters thereof | |
US5716949A (en) | Heterocyclic compounds | |
US6071901A (en) | Substituted dibenz[b,f]azepines and uses thereof | |
EP0851865B1 (en) | 12H-Dibenzo[d,g][1,3]dioxocine derivatives | |
US6613791B1 (en) | N-substituted azaheterocyclic carboxylic acids and their use | |
US5962449A (en) | Tricyclic compounds in treating hyperalgesic conditions and NIDDM | |
US5721260A (en) | Heterocyclic compounds | |
US5952352A (en) | Heterocyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVO NORDISK A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDERSEN, HENRIK SUNE;ANDERSEN, KNUD ERIK;MADSEN, PETER;AND OTHERS;REEL/FRAME:007989/0389;SIGNING DATES FROM 19960419 TO 19960430 |
|
CC | Certificate of correction | ||
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20060210 |